Prot #CX-839-003: A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Relapsed and/or Treatment-Refractory Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date3/19/143/19/20

Funding

  • SCRI Development Innovations, LLC (Prot #CX-839-003)
  • Calithera Biosciences, Inc. (Prot #CX-839-003)